BACKGROUND: Patients with localized esophageal and esophagogastric junction cancer (EAC) receive chemoradiation and then surgery (trimodality, TMT) or definitive chemoradiation (bimodality, BMT). Distant metastases (DMs) are common but the details of their distribution and timing in a large cohort have not been described. METHODS: 629 patients with localized EAC who had TMT or BMT were analyzed. Standard statistical methods were used to define the end points. RESULTS: The median follow-up time was 37.2 months (interquartile range 17.8-65.0). Of 356 TMT patients, 33% (119) developed DM as their first relapse and of 273 BMT patients, 40% (109) developed DM; 91% (TMT) and 96% (BMT) of the DMs were diagnosed within 2 years of local therapy. The most common sites of DM were: lung, distant nodes, liver, peritoneal cavity, bone, brain and pleura in order of frequency. The median overall survival of TMT patients with DM was 10.2 months (95% CI 7.8-12.7) and that for BMT patients with DM was 7.8 months (95% CI 5.7-9.9). CONCLUSIONS: Following TMT or BMT, ≥33% of patients developed DMs and most of these occurred within 2 years (>90%) of local therapy. A clinical model is desirable that associates clinical parameters with a high risk for DM in TMT-eligible patients prior to surgery.
BACKGROUND:Patients with localized esophageal and esophagogastric junction cancer (EAC) receive chemoradiation and then surgery (trimodality, TMT) or definitive chemoradiation (bimodality, BMT). Distant metastases (DMs) are common but the details of their distribution and timing in a large cohort have not been described. METHODS: 629 patients with localized EAC who had TMT or BMT were analyzed. Standard statistical methods were used to define the end points. RESULTS: The median follow-up time was 37.2 months (interquartile range 17.8-65.0). Of 356 TMT patients, 33% (119) developed DM as their first relapse and of 273 BMT patients, 40% (109) developed DM; 91% (TMT) and 96% (BMT) of the DMs were diagnosed within 2 years of local therapy. The most common sites of DM were: lung, distant nodes, liver, peritoneal cavity, bone, brain and pleura in order of frequency. The median overall survival of TMT patients with DM was 10.2 months (95% CI 7.8-12.7) and that for BMT patients with DM was 7.8 months (95% CI 5.7-9.9). CONCLUSIONS: Following TMT or BMT, ≥33% of patients developed DMs and most of these occurred within 2 years (>90%) of local therapy. A clinical model is desirable that associates clinical parameters with a high risk for DM in TMT-eligible patients prior to surgery.
Authors: P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast Journal: N Engl J Med Date: 2012-05-31 Impact factor: 91.245
Authors: Arya Amini; Jaffer Ajani; Ritsuko Komaki; Pamela K Allen; Bruce D Minsky; Mariela Blum; Lianchun Xiao; Akihiro Suzuki; Wayne Hofstetter; Stephen Swisher; Daniel Gomez; Zhongxing Liao; Jeffrey H Lee; Manoop S Bhutani; James W Welsh Journal: Ann Surg Oncol Date: 2013-11-07 Impact factor: 5.344
Authors: Jaffer A Ajani; James S Barthel; David J Bentrem; Thomas A D'Amico; Prajnan Das; Crystal S Denlinger; Charles S Fuchs; Hans Gerdes; Robert E Glasgow; James A Hayman; Wayne L Hofstetter; David H Ilson; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; A Craig Lockhart; Mary F Mulcahy; Mark B Orringer; Raymond U Osarogiagbon; James A Posey; Aaron R Sasson; Walter J Scott; Stephen Shibata; Vivian E M Strong; Thomas K Varghese; Graham Warren; Mary Kay Washington; Christopher Willett; Cameron D Wright Journal: J Natl Compr Canc Netw Date: 2011-08-01 Impact factor: 11.908
Authors: J S Cooper; M D Guo; A Herskovic; J S Macdonald; J A Martenson; M Al-Sarraf; R Byhardt; A H Russell; J J Beitler; S Spencer; S O Asbell; M V Graham; L L Leichman Journal: JAMA Date: 1999-05-05 Impact factor: 56.272
Authors: Kazuki Sudo; Takashi Taketa; Arlene M Correa; Maria-Claudia Campagna; Roopma Wadhwa; Mariela A Blum; Ritsuko Komaki; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; Heath D Skinner; Dipen M Maru; David C Rice; Stephen G Swisher; Wayne L Hofstetter; Jaffer A Ajani Journal: J Clin Oncol Date: 2013-10-21 Impact factor: 44.544
Authors: James Welsh; Stephen H Settle; Arya Amini; Lianchun Xiao; Akihiro Suzuki; Yuki Hayashi; Wayne Hofstetter; Ritsuko Komaki; Zhongxing Liao; Jaffer A Ajani Journal: Cancer Date: 2011-10-05 Impact factor: 6.860
Authors: Bo Jan Noordman; Bas P L Wijnhoven; Sjoerd M Lagarde; Jurjen J Boonstra; Peter Paul L O Coene; Jan Willem T Dekker; Michael Doukas; Ate van der Gaast; Joos Heisterkamp; Ewout A Kouwenhoven; Grard A P Nieuwenhuijzen; Jean-Pierre E N Pierie; Camiel Rosman; Johanna W van Sandick; Maurice J C van der Sangen; Meindert N Sosef; Manon C W Spaander; Roelf Valkema; Edwin S van der Zaag; Ewout W Steyerberg; J Jan B van Lanschot Journal: BMC Cancer Date: 2018-02-06 Impact factor: 4.430
Authors: Moniek Hp Verstegen; Mitchell Harker; Carlijn van de Water; Jolanda van Dieren; Niek Hugen; Iris D Nagtegaal; Camiel Rosman; Rachel S van der Post Journal: World J Gastroenterol Date: 2020-10-21 Impact factor: 5.742